MOLOGEN AG
MOLOGEN AG presented subgroup analysis from IMPACT study and design of pivotal IMPALA trial at Gastrointestinal Cancers Symposium 2015
MOLOGEN AG / Key word(s): Study/Study results MOLOGEN AG presented subgroup analysis from IMPACT study and design of pivotal IMPALA trial at Gastrointestinal Cancers Symposium 2015 Berlin, January 19, 2015 – The biotechnology company MOLOGEN AG presented two posters on the cancer immunotherapy MGN1703 at the Gastrointestinal Cancers Symposium 2015 in San Francisco, California. The first poster featured promising data on overall survival of patient subgroups from the IMPACT study in colorectal cancer. The data suggests that responders to induction therapy may benefit the most from a switch maintenance treatment with MGN1703. This is reflected in the pivotal study IMPALA where ‘response to induction therapy’ is one of the main inclusion criteria. The second poster outlined the design of the IMPALA trial, which has been already started in 2014 and is currently enrolling patients. “We are pleased that the predictive factors previously shown to indicate a more promising progression free survival are also applicable for overall survival. The IMPALA study design is based on these findings. IMPALA will only include patients with response after induction therapy. These patients seem to be the best candidates to benefit most from the MGN1703 immunotherapy,” said Prof. Dr. Dirk Arnold, MD, Director of the Clinic for Medical Oncology, Klinik für Tumorbiologie, Freiburg, Germany. He is one of the study investigators of IMPACT, one of the coordinating study investigators of IMPALA and also a member of the steering committee of IMPALA. Further to the IMPALA trial in colorectal cancer, MGN1703 is being investigated for first-line maintenance treatment of extensive-stage small cell lung cancer, a serious cancer disease with high unmet medical need. IMPULSE, an international randomized controlled trial, is currently enrolling patients as well.
Patients included in the IMPACT study had stabilization, or partial or complete remission of their disease after receiving first-line therapy for 4.5 to 6 months. The patients were randomized to receive either MGN1703 or placebo twice per week. The treatment was continued until tumor progression was observed. The primary endpoint of the study was to determine progression-free survival of the patients. Secondary study endpoints included overall survival, progression-free survival from start of induction therapy, response rates and safety, as well as collection of immunological and pharmacodynamic data. About IMPALA Leading medical associations will collaborate: Arbeitsgemeinschaft Internistische Onkologie (AIO) in Germany, Grupo Españiol de Tratamiento de Tumores Digestivos (TTD) in Spain and Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) in France. The steering committee consists of international medical experts; among others the coordinating study investigators Prof. David Cunningham, MD, Department of Medicine and Director of Clinical Research, Royal Marsden Hospital in London, and Prof. Dirk Arnold, MD, Director of the Clinic for Medical Oncology, Klinik für Tumorbiologie, Freiburg, Germany. For more information on the trials IMPACT and IMPALA please visit www.clinicaltrials.gov. About MGN1703 MOLOGEN AG The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
Note about risk for future predictions
2015-01-19 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart | |
End of News | DGAP News-Service |
314295 2015-01-19 |